COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,969 Articles (22,604 medRxiv, 8,365 bioRxiv)

Most recent first Previous |  Page 448: Articles 4471-4480  | Next

Application of comprehensive evaluation framework to Coronavirus Disease 19 studies: A systematic review of translational aspects of artificial intelligence in health care
Casey, A. E., Ansari, S., Nakisa, B., Kelly, B., Brown, P., Cooper, P., Muhammad, I., Livingstone, S., Reddy, S., Makinen, V.-P. E.
10.1101/2023.02.23.23286374 — Posted: 2023-02-26
Task shifting healthcare services in the post-COVID world: A scoping review
Das, S., Grant, L.
10.1101/2023.02.26.23286301 — Posted: 2023-02-26
Cellular and molecular heterogeneities and signatures, and pathological trajectories of fatal COVID-19 lungs defined by spatial single-cell transcriptome analysis
Das, A., Meng, W., Liu, Z., Hasib, M. M., Galloway, H., da Silva, S. R., Chen, L., Sica, G. L., Paniz-Mondolfi, A., Bryce, C., Grimes, Z., Sordillo, E. M., Cordon-Cardo, C., Rivera, K. P., Flores, M., Chiu, Y.-C., Huang, Y., Gao, S.-J.
10.1101/2023.02.24.23286388 — Posted: 2023-02-26
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents
Lopez, P., Bravo, L., Buntinx, E., Borja-Tabora, C., Velasquez, H., Rodriguez, E. J., Rodirguez, C. A., Carlos, J., Montellano, M. E. B., Alberto, E. R., Salvani-Bautista, M., Huang, Y., Hu, B., Li, P., Han, H. H., Baccarini, C., Smolenov, I.
10.1101/2023.02.22.23286317 — Posted: 2023-02-26
Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials
Smith, K., Hegazy, K., Cai, M. R., McKnight, I., Rousculp, M. D., Alves, K.
10.1101/2023.02.24.23285601 — Posted: 2023-02-26
A Snapshot of COVID-19 Incidence, Hospitalizations, and Mortality from Indirect Survey Data in China in January 2023
Ramirez, J. M., Diaz-Aranda, S., Aguilar, J., Ojo, O., Lillo, R. E., Fernandez Anta, A.
10.1101/2023.02.22.23286167 — Posted: 2023-02-26
Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control
Larsen, S. L., Shin, I., Joseph, J., West, H., Anorga, R., Mena, G. E., Mahmud, A., Martinez, P. P.
10.1101/2023.02.23.23286326 — Posted: 2023-02-26
Disability evaluation in patients with Guillain-Barre syndrome and SARS-CoV-2 infection from a neurological reference center in Peru
Sanchez-Boluarte, S. S., Aguirre-Quispe, W., Sanchez Boluarte, A. N., Tacunan Cuellar, J., Segura Chavez, D. A.
10.1101/2023.02.22.23286287 — Posted: 2023-02-26
Machine learning on large scale perturbation screens for SARS-CoV-2 host factors identifies β-catenin/CBP inhibitor PRI-724 as a potent antiviral
Kelch, M. A., Vera-Guapi, A. L., Beder, T., Oswald, M., Hiemisch, A., Beil, N., Wajda, P., Ciesek, S., Erfle, H., Toptan, T., König, R.
10.1101/2023.02.23.529833 — Posted: 2023-02-24
Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution
Sunagawa, J., Kim, K. S., Park, H., Komorizono, R., Choi, S., Torres, L. R., Woo, J., Jeong, Y. D., Hart, W. S., Thompson, R. N., Aihara, K., Iwami, S., Yamaguchi, R.
10.1101/2023.02.23.529742 — Posted: 2023-02-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).